THE USE OF VIRAL VECTORS IN GENE TRANSFER THERAPY
Abstract
Gene therapy is strategy based on using genes as pharmaceuticals. Gene therapy is a treatment that involves altering the genes inside body's cells to stop disease. Genes contain DNA- the code controlling body form and function. Genes that do not work properly can cause disease. Gene therapy replaces a faulty gene or adds a new gene in an attempt to cure disease or improve the ability of the body to fight disease. Gene therapy holds promise for treating a wide range of diseases, including cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. Various types of genetic material are used in gene therapy; double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), plasmid DNA and antisense oligodeoxynucleotides (ASON). The success of gene therapy depends on assuring the entrance of the therapeutic gene to targeted cells without any form of biodegradation. Commonly used vectors in gene therapy are: adenoviruses (400 clinical studies; 23.8%), retroviruses (344 clinical studies; 20.5%), unenveloped/plasmid DNA (304 clinical studies, 17.7%), adeno-associated viruses (75 clinical studies; 4.5%) and others. In this paper, we have reviewed the major gene delivery vectors and recent improvements made in their design meant to overcome the issues that commonly arise with the use of gene therapy vectors.
Keywords:
Adenoviruses, Bacteriophages, gene therapy, Retroviruses, viral vectorDOI
https://doi.org/10.25004/IJPSDR.2016.080301References
Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit. 2005; 11(4):RA110-21.
Valenčáková A, Dziaková A, Hatalová E. Gene therapy of cancerous diseases. Int. J. Pharm. Sci. Drug Res. 2015; 7(6):444-450.
Rochlitz CF. Gene therapy of cancer. Swiss Med Wkly. 2001; 131:1-2, 4-9.
Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV infection, Gene Ther. 1994; 1(1):13-26.
Dishart KL, Work LM, Denby L, Baker AH. Gene Therapy for Cardiovascular Disease. J Biomed Biotechnol. 2003; 2:138-148.
Bunnell BA, Morgan RA. Gene therapy for infectious diseases. Clin Microbiol Rev. 1998; 11(1):42-56.
Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3(7):477-88.
Zhang J, Frolov I, Russell SJ. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med. 2004; 6(10):1082-91.
Bazeley R., http://www.phgfoundation.org/news/11189/ (10.Oct.2015)
Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013; 525(2):162-9.
Wysocki PJ, Grabarczyk P, Mackiewicz-Wysocka M, Kowalczyk DW, Mackiewicz A. Genetically modified dendritic cells--a new, promising cancer treatment strategy? Expert Opin Biol Ther. 2002; 2(8):835-45.
Stribley JM, Rehman KS, Niu H, Christman GM. Gene therapy and reproductive medicine, Fertil Steril. 2002; 77(4):645-57.
Sandhu JS, Keating A, Hozumi N. Human gene therapy. Crit Rev Biotechnol. 1997; 17(4):307-26. Review.
Knipe JM, Peters JT, Peppas NA. Theranostic agents for intracellular gene delivery with spatiotemporal imaging. Nano Today 2013; 8(1):21-38.
Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ, Choi JS, Park JS. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009; 30(4):665-73.
Ropert C. Liposomes as a gene delivery system, Braz J Med Biol Res. 1999; 32(2):163-9.
Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet. 2000; 1(2):91-9.
Chailertvanitkul VA, Pouton CW. Adenovirus: a blueprint for non-viral gene delivery. Curr Opin Biotechnol. 2010; 21(5):627-32.
Wiley John, Sons I. Gene therapy clinical trials worldwide, In: The Journal of Gene Medicine, March 17th 2010, Available from: <http://www.wiley.com/legacy/wileychi/genmed/clinical/>
Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001; 7(1):33-40.
Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm. 2014; 459(1-2):70-83.
Boulaiz H, Prados J, Marchal JA, Melguizo C, Concha A, Carrillo E, Vélez C, Martínez A, Aránega A. Modulation of Ki-67 expression and morphological changes induced by gef gene in MCF-7 human breast cancer cells. Cell Mol Biol (Noisy-le-grand) 2005; 51(1):87-92.
Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression, Br J Pharmacol. 2009; 157(2):153-65.
Munier S, Delcroix-Genête D, Carthagéna L, Gumez A, Hazan U. Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. Retrovirology 2005; 2:73.
Templeton NS. Cationic liposome-mediated gene delivery in vivo. Biosci Rep. 2002; 22(2):283-95.
Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60(2):249-71.
Kämmer C, Doerfler W. Genomic sequencing reveals absence of DNA methylation in the major late promoter of adenovirus type 2 DNA in the virion and in productively infected cells. FEBS Lett. 1995; 362(3):301-5.
Sprengel J, Schmitz B, Heuss-Neitzel D, Doerfler W. The complete nucleotide sequence of the DNA of human adenovirus type 12. Curr Top Microbiol Immunol. 1995; 199(2):189-274.
Gardlik R, Celec P , Bernadic M. Targeting angiogenesis for cancer (gene) therapy. Bratisl Lek Listy. 2011; 112(8):428-34.
Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33.
Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterlé A, Michou AI, Pavirani A, Mehtali M. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response, Immunol Lett. 1997; 57(1-3):19-25.
Gorziglia MI, Kadan MJ, Yei S, Lim J, Lee GM, Luthra R, Trapnell BC. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol. 1996; 70(6):4173-8.
Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, Graham FL, Kochanek S, Bett AJ, Caskey CT. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998; 95(14):7866-71.
Kovesdi I, Brough DE, Bruder JT, Wickham TJ, Adenoviral vectors for gene transfer. Curr Opin Biotechnol. 1997; 8(5):583-9.
O´Keefe EP. Nucleic Acid Delivery: Lentiviral and Retroviral Vectors. In Mather Methods 2013; 3:174.
Wysocki PJ, Mackiewicz-Wysocka M, Mackiewicz A. Cancer gene therapy state of the art. Reports of practical oncology and radiotherapy 2002; 7(4):149-155.
Miller RJ Jr, Bahnson RR, Banner B, Ernstoff MS, O'Donnell WF. Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder. Cancer 1990; 65(2):207-10.
http://www.willey.com/genetherapy/clinical (10.Oct.2015)
Maier P, von Kalle C, Laufs S. Retroviral vectors for gene therapy. Future Microbiol. 2010; 5(10):1507-23.
http://library.thinkquest.org/28000/load_image.php3?id=51 (10. Oct. 2015)
Yang S, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther. 1999; 10(1):123-32.
Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990; 323(9):570-8.
Vigna E, Naldini L, Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2(5):308-16.
Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. 1995; 2(6):357-62.
Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet. 2009; 67:29-60.
Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol. 2006; 24(5):212-8.
Szybalska EH, Szybalski W. Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc Natl Acad Sci U S A 1962; 48:2026-34.
Larocca D, Kassner PD, Witte A, Ladner RC, Pierce GF, Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 1999; 13(6):727-34.
Piersanti S, Martina Y, Cherubini G, Avitabile D, Saggio I. Use of DNA microarrays to monitor host response to virus and virus-derived gene therapy vectors. Am J Pharmacogenomics 2004; 4(6):345-56.
Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest. 1998; 102(2):430-7.
Published
Abstract Display: 341 
PDF Downloads: 426 How to Cite
Issue
Section
Copyright (c) 2016 A. Dziaková, A. Valenčáková, E. Hatalová, J. Kalinová
This work is licensed under a Creative Commons Attribution 4.0 International License.
